DIA
Drug Information Association Logo

Evaluation of Pain Drugs: Role of Undetected Underlying Sleep Pathologies

Time

Wed, Jun 26 11:45AM
W 10

Title

Evaluation of Pain Drugs: Role of Undetected Underlying Sleep Pathologies

Abstract Summary

A retrospective analysis was performed on a 5-week placebo-controlled crossover study on 63 patients (67 ± 4 (sd) years old) with osteoarthritis of the knee and a baseline pain intensity score = 4 on a 0-10 scale. The placebo and treatment (celecoxib, 100mg bid) weeks were each preceded by 1-week baselines with a 1-week wash-out period between the drug administration weeks. Sleep and daytime activity were monitored throughout the study with wrist actigraphy. The actigraphy data collected during the first week of the study (Baseline 1) was used to retrospectively partition the group into those subjects whose mean minutes of wake-after-sleep-onset per night (WASO) was less than 60 minutes (normal sleep) and those with WASO>60 min (possible underlying sleep pathology). A meta-analysis of normal WASO as a function of age suggests that 60 minutes is a reasonable upper limit of normal value for this age group (Ohayon, et al. Sleep 27: 1255-73, 2004). Pain was assessed each day using a patient reported pain score (0-10) corrected for the daily level of activity measured with wrist actigraphy. Changes in reported pain were calculated as the mean pain score during the treatment week minus the value during the placebo week.`

Poster Presenter

Barry Peterson
PhD,
Sr. Manager, Clinical Affairs,
Philips Respironics
United States

© 2015 DIA